Veteran healthcare executive and investor with experience across public and private markets, Renee Pilkenton focuses on commercial strategy, corporate development and governance for biopharma and medtech companies. Background blends operating leadership with transaction oversight, board service and capital-raising advisory; frequently engages with PE and VC investors on go-to-market and licensing outcomes.
Veteran healthcare executive and investor with experience across public and private markets, Renee Pilkenton focuses on commercial strategy, corporate development and governance for biopharma and medtech companies. Background blends operating leadership with transaction oversight, board service and capital-raising advisory; frequently engages with PE and VC investors on go-to-market and licensing outcomes.
Combines healthcare operating experience with investor discipline to back commercially-driven biopharma and medtech opportunities. Prioritizes companies with clear go‑to‑market pathways, durable reimbursement or licensing optionality, and measurable commercial milestones. Prefers stage-flexible capital deployment that de-risks through governance, board engagement and pragmatic corporate development—often partnering with PE/VC to bridge technical value into scalable revenue. Time horizon is medium-to-long, with strict milestone-based risk controls and focus on return via commercialization or strategic exit.
Combines healthcare operating experience with investor discipline to back commercially-driven biopharma and medtech opportunities. Prioritizes companies with clear go‑to‑market pathways, durable reimbursement or licensing optionality, and measurable commercial milestones. Prefers stage-flexible capital deployment that de-risks through governance, board engagement and pragmatic corporate development—often partnering with PE/VC to bridge technical value into scalable revenue. Time horizon is medium-to-long, with strict milestone-based risk controls and focus on return via commercialization or strategic exit.
| Trades 1170 | Longs Won 832/1170 71% | Profit Factor 12.08 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $216,513.03 |
| Average Win $64,241.38 | Best Trade (Oct 23) $3.58M | Sharpe Ratio -11.23 |
| Average Loss -$13,088 | Worst Trade (Oct 14) -$239,470.44 | Z-Score 9.31 (100%) |
| Commissions $0 | Avg. Trade Length 1y 7m 5d | Expectancy $41,901.78 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 12,500 | 11,250 | 10,000 | 8,750 | 7,500 | 6,250 | 5,000 | 3,750 | 2,500 | 1,250 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
A AgileThought, Inc. Class A Common Stock | 3,404 | $409,743.95 | $584,500.84 | - | $174,756.89 | 42.65% | -1.254% |
AAPL Apple Inc. | 26,901 | $5.33M | $9.35M | - | $4.02M | 75.28% | -0.175% |
ABBV AbbVie Inc. | 4,093 | $804,475.65 | $1.16M | - | $357,936.35 | 44.49% | -0.417% |
ABT Abbott Laboratories | 2,628 | $238,465.23 | $269,317.44 | - | $30,852.21 | 12.94% | -0.029% |
ADP Automatic Data Processing Inc. | 5,689 | $1.26M | $1.74M | - | $486,377.41 | 38.7% | -0.49% |
AGG iShares Core U.S. Aggregate Bond ETF | 29,743 | $2.83M | $2.85M | - | $24,960.86 | 0.88% | -0.161% |
AMD Advanced Micro Devices Inc. | 408 | $237,011.8 | $212,559.84 | - | -$24,451.96 | -10.32% | +2.569% |
AMZN Amazon.com Inc | 7,637 | $1.24M | $1.9M | - | $661,800.35 | 53.4% | -0.579% |
APH Amphenol Corp. Class A Common Stock | 4,696 | $145,284.85 | $346,846.56 | - | $201,561.71 | 138.74% | +1.081% |
AVDV Avantis International Small Cap Value ETF | 9,239 | $710,728.66 | $970,048.8 | - | $259,320.14 | 36.49% | -0.714% |
AVGO Broadcom Inc. | 2,402 | $505,744.57 | $785,454 | - | $279,709.43 | 55.31% | +1.163% |
AXP American Express Company | 2,568 | $453,976.95 | $809,805.96 | - | $355,829.01 | 78.38% | -3.023% |
BA The Boeing Company | 2,587 | $554,804.85 | $480,535.25 | - | -$74,269.6 | -13.39% | -0.96% |
BAC Bank of America Corporation | 6,072 | $345,364.1 | $307,759.32 | - | -$37,604.78 | -10.89% | -0.773% |
BDX Becton, Dickinson and Company | 2,811 | $583,437.1 | $558,039.72 | - | -$25,397.38 | -4.35% | -0.948% |
BKNG Booking Holdings Inc. | 1,755 | $227,851.67 | $275,517.45 | - | $47,665.78 | 20.92% | -2.551% |
BLK BlackRock, Inc. | 421 | $430,029.33 | $474,883.79 | - | $44,854.46 | 10.43% | -0.818% |
BMY Bristol-Myers Squibb Company | 29,306 | $1.87M | $1.8M | - | -$73,045.18 | -3.9% | -2.46% |
BND Vanguard Total Bond Market ETF | 47,027 | $3.44M | $3.35M | - | -$85,633.41 | -2.49% | -0.168% |
BNY Bank of New York Mellon Corp. | 7,046 | $314,101.85 | $1.02M | - | $705,313.43 | 224.55% | -0.44% |